ProMIS Neurosciences Announces that Chief Scientific Officer, Dr. Neil Cashman, to Address Annual Meeting of the American Neurological Association (ANA)
Noted Physician and Scientist to Address the Role of Prions in Neurodegenerative Diseases
TORONTO, CANADA–September 29, 2015–ProMIS Neurosciences, Inc. (TSX: PMN), announced today that its Chief Scientific Officer and co-founder, Dr. Neil Cashman, will be addressing the American Neurological Association’s 140th Annual Meeting on Tuesday, September 29th in Chicago.
Dr. Cashman will be part of the program’s prestigious Presidential Symposium and will be joined by Chairs: Drs. Robert H. Brown, Jr., University of Massachusetts Medical School, and Henry Paulson, University of Michigan Health System. Fellow faculty members include: Drs. John Collinge, UCL Institute of Neurology, Mark Diamond, University of Texas Southwestern and J. Paul Taylor, St. Jude Children’s Research Hospital.
About this Important Symposium
The title of the symposium is Evolving Concepts in Prion Biology: How Many Neurodegenerative Diseases are Caused by Prions?
There is an emerging consensus in the neuroscience community that propagating, misfolded proteins (called prions) are fundamental drivers of multiple neurodegenerative diseases, including Alzheimer’s, ALS and Parkinson’s Disease. This increased understanding raises the prospect for developing a new class of breakthrough therapies targeting misfolded, neurotoxic forms of beta amyloid, SOD1, and Tau.
About Dr. Cashman
Dr. Cashman is a neurologist and scientist focused on neurodegenerative diseases. Professor Cashman is currently in the Faculty of Medicine at the University of British Columbia, in Vancouver where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine solutions for the early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.
ProMIS uses its computational discovery platform—ProMISTM–to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns the exclusive rights to the genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target. For further information please consult the Company’s website at:
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise
For inquiries please contact:
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783